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Introduction
Targeted therapy for breast cancer was actually used, albeit
unwittingly, as early as the late 1800s. Beatson first surgically
removed the ovaries of women to treat metastatic breast
cancer in 1896 [1], while Schinzinger recommended ovarian
irradiation as adjuvant therapy in 1889 [2]. Ovarian ablation
and subsequently diethylstilbestrol were initially used to treat
breast cancer without knowing the target to which they were
directed. More than 50 years later Jensen and Jacobson
discovered the oestrogen receptor (ER) [3], which was
subsequently understood to be the target or partial target of
these endocrine approaches.
It is now known that women whose tumours are ER-negative
and progesterone receptor (PgR)-negative have less than a
5% chance of responding to endocrine therapies, while those
whose tumours are ER-positive and/or PgR-positive have a
chance of response of somewhere between 40 and 70%. It
was believed that having both receptors positive improved
the response rate or benefit from adjuvant endocrine therapy
for many years, but is now felt that the ER serves as the major
predictive factor. The PgR is felt to give some prognostic
value but not to be associated with better response to
endocrine therapy in the adjuvant or the metastatic setting [4]
(R. Peto, personal communication).
For a number of years there was controversy about whether
tamoxifen might be effective in ER-negative as well as ER-
positive patients. Even the large Oxford Overview [5] did not
initially display this clearly for some long time, and it was in
fact from other studies with carefully controlled biomarkers
that the role of ER in predictory effectiveness became more
clear [6,7]. This experience provides lessons for the future, in
that large meta-analyses in which markers may have been
measured by a variety of methods may not be the best way of
sorting out these matters. Even today there is ongoing
controversy regarding the role of the ER and response to
chemotherapy. It is generally felt that highly ER-positive
patients may respond less well to chemotherapy. Certainly
high ER and PgR levels have an inverse link to proliferative
indices such as Ki-67, which tend to predict more strongly for
response to chemotherapy.
We now have the 21-gene OncotypeDX recurrence score
that may be used as a continuous variable both to predict
benefit from tamoxifen and to predict response from those
treated with tamoxifen [8-11]. It has also been shown that the
OncotypeDX recurrence score correlates more strongly with
outcome in tamoxifen-treated patients than the Adjuvant
online program and that the OncotypeDX recurrence score is
also predictive of local recurrence in tamoxifen-treated
patients [12]. The OncotypeDX assay is now being studied in
the TAILORx study – in which women with a recurrence
score <11 will receive hormonal therapy only and women
with a recurrence score >25 will receive hormonal therapy
and chemotherapy, while women with an intermediate recur-
rence score of 11 to 25 will be randomized to receive
hormonal therapy alone with or without chemotherapy. The
OncotypeDX recurrence score may serve as a prognostic
and predictive factor; that is, predicting both the chance of
recurrence and the potential efficacy of hormonal and/or
chemotherapy. Being a combination of 21 genes, however,
the variable is not really a target as such. Furthermore, the
assay is constituted mainly of genes representing ER,
proliferation and HER2.
The HER2 protein and gene proved not only to have
prognostic value [13,14] but also to be a genuine target that
could be targeted for a specific response. The first treatment
directed toward the HER2 oncoprotein was trastuzumab
(Herceptin), a humanized monoclonal anti-HER2 antibody
that produced 15% response rates as a single agent in
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HER2-positive patients [15] and significantly added to
progression-free survival and overall survival in women with
metastatic disease treated with several types of chemo-
therapy [16]. Concordance between local and central labora-
tories in determining HER2 has been problematic, and some
patients who have been declared HER2-negative on central
review in large trials have nonetheless received benefit from
Herceptin. This is being further explored. Although HER2 is
clearly a bona fide target for anti-HER2 therapies such as
Herceptin, lapatinib (Tykerb) and others, problems with its
measurement and with the fact that only ~15% of those who
are HER2-positive actually seem to benefit remain a
challenge. Interestingly HER2 has an inverse relationship with
the ER and PgR [17]. HER2 is also involved in endocrine
resistance [18,19]. Endocrine resistance may in part be
reversible by adding a HER2-targeted agent, as has been
done in the TANDEM trial [20].
Many of us have attempted to use HER2 measurements to
predict differential response to anthracyclines, and this
seems to be reliable although not all data are consistent [21-
23]. Some feel that HER2 is predictive in this setting only
because it is located on the topoisomerase IIα gene of
chromosome 17, topoisomerase II α being an enzyme that is
directly involved in the mechanism of action of anthracyclines
against human cancers. Topoisomerase IIα gene amplifica-
tion and HER2/neu gene amplification and protein over-
expression are closely related, and each predict for
responsiveness to anthracyclines in some randomized trials
comparing anthracycline-containing versus nonanthracycline-
containing regimens [21,24]. Furthermore, topoisomerase II
protein overexpression also appears to predict for differential
anthracycline benefit, although it seems less closely related
to topoisomerase IIα overexpression and/or HER2/neu [25].
A meta-analysis of phase III trials evaluating the predictive
value of HER2 and topoisomerase IIα in early breast cancer
patients treated with cyclophosphamide, methotrexate and
5-FU (CMF) versus anthracycline-based adjuvant therapy did
not show a strongly statistically significant predictive value
[26], particularly when the large British NEAT and BR9601
studies were included (J. Bartlett, personal communication).
Some investigators now believe that chromosome 17
polysomy is a more appropriate predictive marker [27,28].
The predictive value of these particular gene and protein
changes remains to be clarified but it seems unlikely that they
actually represent targets in the same way as HER2 is a
target of Herceptin.
Additionally, targeted anti-HER2 agents such as lapatinib
were meant to be effective against HER1 and HER2 over-
expressing tumours but have proved to affect only individuals
with HER2-positive tumours. Newer drugs such as beva-
cizumab – an antivascular endothelial growth factor antibody –
are effective, but one cannot find a target that selects
subgroups of patients in whom it is more valuable [29].
Some targeted therapies, including the endocrine therapies
and trastuzumab, are therefore clearly available and can be
directed in effective, albeit less than perfect, ways towards
specified and relatively well measured targets. Some of the
new biologics or so-called targeted agents such as
bevacizumab and lapatinib, however, are not as clearly
directed towards their targets as might have been initially
predicted. I would therefore conclude that tailored targeted
therapy for all may be worthwhile but is not yet realistic.
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